Literature DB >> 7699050

Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.

A L Barry1, P C Fuchs, S D Allen, F C Tenover, J H Jorgensen, L B Reller.   

Abstract

For testing bacterial susceptibility to PD131628, a 5-micrograms disk and the following tentative interpretive criteria may be used: > or = 19 mm for susceptible (MIC, < or = 1.0 micrograms/ml), 16 to 18 mm for intermediate (MIC, 2.0 micrograms/ml), and < or = 15 mm for resistant (MIC, > or = 4.0 micrograms/ml). For standard quality control strains, the following limits are proposed: for Escherichia coli ATCC 25922, zones of 31 to 41 mm or a MIC of 0.002 to 0.016 micrograms/ml; for Pseudomonas aeruginosa ATCC 27853, zones of 26 to 34 mm or a MIC of 0.12 to 0.5 micrograms/ml; for Staphylococcus aureus ATCC 25923, zones of 27 to 33 mm; for Staphylococcus aureus ATCC 29213, a MIC of 0.03 to 0.12 micrograms/ml; and for Enterococcus faecalis ATCC 29212, a MIC of 0.12 to 0.5 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7699050      PMCID: PMC227918          DOI: 10.1128/jcm.33.1.235-238.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

2.  Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

Authors:  P C Fuchs; A L Barry; M A Pfaller; S D Allen; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.

Authors:  M S Barrett; R N Jones; M E Erwin; D M Johnson; B M Briggs
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Sep-Oct       Impact factor: 2.803

4.  Antibacterial activity of PD 131628 and proposed disc diffusion susceptibility test criteria.

Authors:  P C Fuchs; A L Barry; M A Pfaller
Journal:  J Antimicrob Chemother       Date:  1994-06       Impact factor: 5.790

5.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

6.  In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.

Authors:  M A Cohen; M D Huband; G B Mailloux; S L Yoder; G E Roland; J M Domagala; C L Heifetz
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

7.  Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.

Authors:  A L Barry; P C Fuchs; D M Citron; S D Allen; H M Wexler
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

8.  In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.

Authors:  A S Ford; A L Baltch; R P Smith; W Ritz
Journal:  J Antimicrob Chemother       Date:  1993-04       Impact factor: 5.790

9.  In-vitro activity of PD 131628, a new quinolone antimicrobial agent.

Authors:  M A Cooper; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1992-05       Impact factor: 5.790

10.  Antibacterial activity of a 1,8-naphthyridine quinolone, PD 131628.

Authors:  C S Lewin
Journal:  J Med Microbiol       Date:  1992-05       Impact factor: 2.472

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.